Click image to enlarge
The
V-PLEX platform offers analytically validated singleplex and multiplex assay kits. Developed under rigorous design control, V-PLEX kits provide accurate and reproducible results with consistency from lot to lot. The V-PLEX Plus Viral Panel 1 (human) Kit includes four biomarkers that are associated with the immune response to viral infection (Table 1). The assays can be used for quantitative measurements of the sample type(s) listed in the “Specifications” tab below and offer detection limits (LLODs and LLOQs) in the sub- to low pg/mL range.
V-PLEX Plus kits include controls, wash buffer, and plate seals.
| Analyte | LLOD | LLOQ | ULOQ | Dynamic Range | Unit | | IL-1β | 0.05 | 0.646 | 375 | 0.05 - 375 | pg/mL |
| IL-6 | 0.06 | 0.633 | 488 | 0.06 - 488 | pg/mL |
| IL-8 | 0.07 | 0.591 | 375 | 0.07 - 375 | pg/mL |
| TNF-α | 0.04 | 0.69 | 248 | 0.04 - 248 | pg/mL |
-
-
Specifications
-
Kit Contents
-
Documentation
-
References
|
Application(s)
|
|
Cytokines & Chemokines
,
Immunology/Inflammation
|
|
|
Analyte(s)
|
|
IL-1β, IL-6, IL-8, TNF-α
|
|
|
Species
|
|
Human
|
|
|
Instrument(s)
|
|
SECTOR Imager 2400
,
MESO QuickPlex SQ 120MM
,
MESO SECTOR S 600
,
SECTOR Imager 6000
,
MESO SECTOR S 600MM
,
MESO QuickPlex SQ 120
|
|
|
Plate Type
|
|
96-well
|
|
|
Sample Type
|
|
Serum, Plasma, Urine, Cell Culture Supernatant
|
|
|
Usage Statement
|
|
For Research Use Only. Not for use in diagnostic procedures.
|
|
|
Storage Condition
|
|
Multi-Component
|
|
|
Schedule B Code
|
|
3822.19.0000
|
|
|
Product Description
|
Storage
|
Quantity per Kit
|
|
Proinflammatory Panel 1 Human Control 1
|
2-8 °C
|
1 vial
(1 vial)
|
|
|
|
Proinflammatory Panel 1 Human Control 2
|
2-8 °C
|
1 vial
(1 vial)
|
|
|
|
Proinflammatory Panel 1 Human Control 3
|
2-8 °C
|
1 vial
(1 vial)
|
|
|
|
|
2-8 °C
|
1 vial
(1 vial)
|
|
|
|
|
2-8 °C
|
1 vial
(75 μL)
|
|
|
|
|
2-8 °C
|
1 vial
(75 μL)
|
|
|
|
|
2-8 °C
|
1 vial
(75 μL)
|
|
|
|
|
2-8 °C
|
1 vial
(75 μL)
|
|
|
|
Proinflammatory Panel 1 (human) Plate
|
2-8 °C
|
1 each
(1 plate)
|
|
|
|
Diluent Assembly 1 (includes Diluent 2 – 8 mL, Diluent 3 – 5 mL)
|
≤-10 °C
|
1 each
|
|
|
|
|
RT
|
1 bottle
(100 mL)
|
|
|
|
|
RT
|
1 bottle
(50 mL)
|
|
|
|
Product Description
|
Storage
|
Quantity per Kit
|
|
Proinflammatory Panel 1 Human Control 1
|
2-8 °C
|
5 vial
(1 vial)
|
|
|
|
Proinflammatory Panel 1 Human Control 2
|
2-8 °C
|
5 vial
(1 vial)
|
|
|
|
Proinflammatory Panel 1 Human Control 3
|
2-8 °C
|
5 vial
(1 vial)
|
|
|
|
|
2-8 °C
|
5 vial
(1 vial)
|
|
|
|
|
2-8 °C
|
1 vial
(375 μL)
|
|
|
|
|
2-8 °C
|
1 vial
(375 μL)
|
|
|
|
|
2-8 °C
|
1 vial
(375 μL)
|
|
|
|
|
2-8 °C
|
1 vial
(375 μL)
|
|
|
|
Proinflammatory Panel 1 (human) Plate
|
2-8 °C
|
5 each
(1 plate)
|
|
|
|
Diluent Assembly 2 (includes Diluent 2 – 40 mL, Diluent 3 – 25 mL)
|
≤-10 °C
|
1 each
|
|
|
|
|
RT
|
1 bottle
(100 mL)
|
|
|
|
|
RT
|
1 bottle
(50 mL)
|
|
|
|
Product Description
|
Storage
|
Quantity per Kit
|
|
Proinflammatory Panel 1 Human Control 1
|
2-8 °C
|
25 vial
(1 vial)
|
|
|
|
Proinflammatory Panel 1 Human Control 2
|
2-8 °C
|
25 vial
(1 vial)
|
|
|
|
Proinflammatory Panel 1 Human Control 3
|
2-8 °C
|
25 vial
(1 vial)
|
|
|
|
|
2-8 °C
|
25 vial
(1 vial)
|
|
|
|
|
2-8 °C
|
5 vial
(375 μL)
|
|
|
|
|
2-8 °C
|
5 vial
(375 μL)
|
|
|
|
|
2-8 °C
|
5 vial
(375 μL)
|
|
|
|
|
2-8 °C
|
5 vial
(375 μL)
|
|
|
|
Proinflammatory Panel 1 (human) Plate
|
2-8 °C
|
25 each
(1 plate)
|
|
|
|
Diluent Assembly 2 (includes Diluent 2 – 40 mL, Diluent 3 – 25 mL)
|
≤-10 °C
|
5 each
|
|
|
|
|
RT
|
5 bottle
(100 mL)
|
|
|
|
|
RT
|
5 bottle
(50 mL)
|
|
|
|
Product Inserts
|
|
|
|
Certificate of analysis
|
|
View More
|
|
SDS
|
|
|
|
Title
|
Journal
|
Year
|
|
Twenty-eight day repeated exposure of human 3D bronchial epithelial model to heated tobacco aerosols indicates decreased toxicological responses compared to cigarette smoke
|
|
|
|
A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma
|
|
|
|
Viral Antigen and Inflammatory Biomarkers in Cerebrospinal Fluid in Patients With COVID-19 Infection and Neurologic Symptoms Compared With Control Participants Without Infection or Neurologic Symptoms
|
|
|
|
Characterization and Biomarker Analyses of Post-COVID-19 Complications and Neurological Manifestations
|
|
|
|
Galectin-9, a Player in Cytokine Release Syndrome and a Surrogate Diagnostic Biomarker in SARS-CoV-2 Infection
|
|
|
|
|
View All
|
Order Details
Catalog No
Size
Price in USD
Qty
Customer Service/Orders
Scientific/Technical Support
Instrument Support
Company Headquarters